Article
This week on the Podcast Dr. Jack Cush reviews the news and journal articles, including the risks of dying, developing RA or autoimmune disease!
All News
Article
RheumNow Live’s 2023 conference led with this year’s hot topic of rheumatoid arthritis, especially what to do regarding pre-clinical RA.
Dr. Kevin Deane started the discussion by mapping out a very complex course of RA, beginning with a person’s genetic and environmental risk factors. What are Dr. Deane’s recommendations for management of pre-RA patients?
Dr. John Cush
Tweet
One in Ten has Autoimmune Disease
A UK population-based study suggests that autoimmune diseases affect approximately one in ten individuals.
https://t.co/a2VbAO0Fc6 https://t.co/69Yl9OTtKY
Dr. John Cush
Tweet
Did you miss Tuesday Night Rheumatology this week?
This webinar features highlights from:
Preclinical RA – To Treat or Not To Treat
Year of the JAKi
Fibroblast/Stromal Cells
https://t.co/yVQLtG6fEe https://t.co/WMXcKdqwdP
Dr. John Cush
Tweet
Another NHANES survey of US adults shows increased prevalence of RA for those exposed to high levels of polycyclic aromatic hydrocarbons (PAH)(OR: 1.8; p=0.02). 90% of the smoking effect on RA risk is mediated by PAH https://t.co/N93MbKspRM https://t.co/uqH75vOZrA
Dr. John Cush
Tweet
Have a Rheumatology question or case for Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/0mC7PxF0DU https://t.co/klbnwjcPbM
Dr. John Cush
Tweet
Study of 481 incident RA:
- no risk of RA w/ tea, alcohol & sugar-soft drinks
- Incr RA risk seen w/ coffee [≥4 vs ≤1cup, HR=1.24;p=0.04] & diet drinks [HR=1.66;never-smokers]
- Reduced RA risk w/ mod EtOH (ever-smokers;HR=0.63) & wine (seropos RA) https://t.co/gPZkTl9rid https://t.co/khYEZYFotl
Dr. John Cush
Tweet
Downs Syndrome (1/700) & autoimmune mechanisms - Downs has a 4-6 fold higher risk of JIA, type 1 diabetes, autoimmune thyroid disease and coeliac disease. https://t.co/wVUDRCS96I https://t.co/RosPAkRnPA
Dr. John Cush
Tweet
DDW 2023 study claims microscopic colitis (MC) pts had a 2fold higher risk of #RA. 11,293 MC pts matched 1:5 w/ population controls. With 8 yrs of F/U, RA was found in 1.1% of MC vs 0.6% controls (adj HR 1.92 (95% CI = 1.56-2.34). https://t.co/R5faYDoaAq https://t.co/qiaOMgOyLR
Dr. John Cush
Tweet
Stop RA trail:
Plaquenil didn’t prevent RA in patient with pre clinical RA. Kevin Deane #RNL2023 @RheumNow https://t.co/gO9QKbAues https://t.co/gEpuBvDpj5
Dr. John Cush
Tweet
#RNL2023 @RheumNow
There are a lot of RA Rx on market now - do we need more?
Dr. Brenner: YES
Stromal targets like LIF/LIFR, Notch3, cadherin-11 offer upstream benefits for our difficult to treat RA patients that don't respond to tradition cs/bDMARDs https://t.co/Og1vvbTRO9 https://t.co/WyqPH0lgkd
Dr. John Cush
Tweet
JAKinib safety takeaways
- avoid in older population 65 yo, malignancy, CV risk, VTE risk
- appropriate in younger pts without VTE/CVD risk factors
#RNL2023 @RheumNow https://t.co/mFvvqJ9Jbp https://t.co/A76tR2S1Rb
Dr. John Cush
Tweet
#RNL2023 @RheumNow
Dr. Stanley Cohen: possible adverse effects of JAKi
-Herpes zoster, other infections
-Malignancy
-Occasional cytopenias
-LFTs (with DMARDs)
-Incr Cr or CPK
-Acne
-Incr lipids
-GI perf
-VTE
Which do you counsel with your patients? https://t.co/zncCw3jlK7 https://t.co/AHhDyxaumM
Dr. John Cush
Tweet
Dr. Stanley Cohen on JAKinibs:
Very concise and informative timeline on the multiple JAKinibs approved for multiple conditions
@RheumNow #RNL2023 https://t.co/ulLh2HikUt https://t.co/0kR8CNZvsV
Dr. John Cush
Tweet
How do you prevent RA in at-risk patient?
Smoking cessation! Healthy weight and exercise! Diet! Periodontal health! 🚭🏋️🥕🦷
Education follow-up!
Not robustly proven to prevent/delay RA, but may be more important than early DMARD intervention! Kevin Deane, MD
#RNL2023
Dr. John Cush
Tweet
STOP-RA study on HCQ preventing RA...
HCQ did NOT prevent RA development in pre-RA pts
@RheumNow #RNL2023 https://t.co/uZRqAxWyyo https://t.co/02qUN4Hhrc
Dr. John Cush
Tweet
QD Clinic - Audience RA Questions from RNL23
Audience Questions & Answers from RNL23 on Rheumatoid Arthritis
https://t.co/vh1Tzstbwl https://t.co/IUXfAlzPoE
Dr. John Cush
Tweet
UK's MHRA has followed EMA final ruling regarding new Safety recs & JAK inhibitors:
- RE: tofacitinib, abrocitinib, baricitinib, upadacitinib & filgotinib use in chr inflammatory Dz.
- avoid JAKi if no suitable alternative: age >=65, smokers, CV/CA Hx https://t.co/Y1vZPHPEPN https://t.co/odovKWebFV
Dr. John Cush
Tweet
Join us this Tuesday for our the start of our May Tuesday Night Rheumatology focusing on Rheumatoid Arthritis: Revolutionary Advances in Therapy
https://t.co/TbNYaGJ3sk https://t.co/DiJwjvUX1d
Dr. John Cush
Tweet
A Danish national registry study compared RA pts taking JAKi (n 875) and bDMARDs (n 4247). They found similar rates of subsequent cancers (14.4 vs 12.9/ per 1000 PYRS); with a nonsignificant risk (HR1.41; CI 0.76, 2.37) https://t.co/wfrlAcij8x https://t.co/OvqKrHw5Wu
